Sameer Ahmed 

Generating real-world evidence (RWE) is increasingly important for pharmaceutical development, post-marketing studies, and regulatory submissions. Collecting high-quality, reliable data from diverse sources such as electronic health records, patient registries, and observational studies requires robust RWE data capture software. Traditional clinical trial platforms often focus on controlled trials and lack the flexibility to handle real-world data efficiently. Early adoption of an integrated platform designed for real-world evidence studies can save time, reduce errors, and improve data integrity.

RWE studies differ from traditional clinical trials because they capture patient outcomes in routine practice rather than controlled experimental conditions. This requires flexible data capture systems that can handle varied data sources, multiple study sites, and ongoing longitudinal tracking. Enterprise EDC systems like Medidata Rave or Veeva are comprehensive but often too rigid and costly for RWE studies. Teams may face long onboarding timelines, technical complexity, and high vendor fees, making them impractical for observational or registry-based research.

Open-source solutions such as REDCap provide a low-cost option but are not fully compliant with 21 CFR Part 11 or GCP, which can create regulatory risk for studies intended to support FDA or EMA submissions. Research teams need a platform that offers both flexibility and compliance while enabling rapid deployment. Capture.Study’s RWE data capture software addresses these challenges by combining speed, usability, and integrated functionality in a single solution.

When evaluating platforms for RWE studies, research teams should consider several critical factors:

1. Flexible Data Capture:
RWE studies involve diverse data sources, including EHRs, registries, and patient-reported outcomes. Choose a platform that allows seamless integration of multiple data types while maintaining data accuracy and consistency.

2. Integrated Features:
Managing RWE studies often requires more than just data collection. Look for platforms that combine EDC, ePRO, eConsent, randomization, and patient enrollment in one system to reduce administrative complexity.

3. Compliance:
Ensure that the platform supports 21 CFR Part 11, GCP, and GDPR compliance. Regulatory adherence is critical, even for observational studies, if the data will be used for decision-making or submissions.